Mentholatum innovates dry-eye care with new Rohto Dry-Aid
ORCHARD PARK, N.Y. — The Mentholatum Company on Wednesday launched Rohto Dry-Aid, a non-blurry tear repair formula that is clinically shown to provide longer lasting dry eye relief versus the leading brand, the company stated.
"With the issue of dry eye on the rise, we've been working with our eye care researchers in Japan for the past five years to come up with a unique product/formula that quickly soothes dry eye symptoms and provides long lasting relief," stated Meryl Reis, VP research and development at the Mentholatum Company. "Now we feel very good to bring to consumers the next generation eye drop for Dry Eye."
Rohto Dry-Aid is designed to relieve the five key symptoms of dry eye: dryness, irritation, grittiness, burning and stinging. In a clinical study it delivered consistent and continuous relief over time and was rated highly for its refreshing feeling while delivering significant improvements in quality of life measures. Unlike over-the-counter dry eye drops that only work on one layer of the tear film, Rohto Dry-Aid is formulated with Liquidshield technology and works in a unique way to restore moisture to the tear film by working on all three layers to mimic a stable, natural tear – soothing eyes for up to 12 hours.
"Designed with consumers in mind, we are certain that the advanced Rohto Dry-Aid formula will help dry eye sufferers enjoy their daily lives, delivering all day relief from irritating and distracting dry eye symptoms, in a refreshing non-blurring eye drop," added Erick Estrada, senior director marketing Mentholatum.
Rohto Dry-Aid features a clear bottle with a single-drop applicator and is currently available at major national and regional retail locations where over-the-counter dry eye drops are sold and also online.
Nature’s Bounty Co. names three new members to its Scientific Advisory Council
RONKONKOMA, N.Y. — The Nature’s Bounty Co. on Tuesday announced that it has appointed three additional members to its Scientific Advisory Council. Chaired by David Katz, The Nature’s Bounty Co. Scientific Advisory Council is a group of scientists who are considered subject matter experts in different areas of science and nutrition. Each member of the Council is selected for the expertise they bring with regard to specific nutrients of interest that align with the benefit platforms around which The Nature’s Bounty Co. innovates.
“With a diverse knowledge base and deep insight into nutrition and health trends, our Scientific Advisory Council is an industry-leading resource that we rely upon to help us best leverage modern science that informs our product innovations,” stated Steve Cahillane, president and CEO of The Nature’s Bounty Co. “Developments in science and nutrition are to thank for many of the creative and innovative new products we have launched on behalf of our Nature’s Bounty, Sundown Naturals, Osteo Bi-Flex, Pure Protein and other brands. We are thankful that our new members have joined us and look forward to their meaningful contributions.”
Joining the council is David Julian McClements, professor at the Department of Food Science at the University of Massachusetts. He specializes in the development of food-based delivery systems for bioactive components, such as vitamins and nutraceuticals, and is the author or editor of more than 10 books. He is currently the most highly cited author in the Agricultural Sciences.
Also joining is Fred Turek, a professor for the Department of Neurobiology, Neurology and Psychiatry as well as the founding Director of the Center for Sleep and Circadian Biology at Northwestern University in Chicago. He is internationally recognized for his studies on the effect of disrupted sleep and circadian rhythm on health and disease.
Finally there is Joseph Petrosino, a professor and interim-chairman of the department of Molecular Virology and Microbiology at Baylor College of Medicine where he is also the director of the Alkek Center for Metagenomics and Microbiome Research. He holds joint appointments in the Baylor College of Medicine Human Genome Sequencing Center and Department of Ophthalmology. Petrosino is the founder and chief scientific officer of Diversigen. He is recognized internationally as an expert on the human microbiome and its role in health and disease.
OTC hearing aid bill poised for House approval, CTA says
ARLINGTON, Va. — The House of Representatives is poised to pass the FDA Reauthorization Act of 2017, which includes the Over-the-Counter Hearing Aid Act, the Consumer Technology Association noted in a release on Tuesday. The act would create a new class of over-the-counter hearing aids and allows non-prescription hearing devices to be marketed to treat mild to moderate hearing loss.
“We applaud Reps. Marsha Blackburn, R-Tenn., and Joe Kennedy III. D-Mass., for working with House Energy and Commerce Committee Chairman Greg Walden, R-Ore., and Ranking Member Frank Pallone. D-N.J., to successfully advance the over-the-counter provision in the broader FDA user fee legislation," stated Gary Shapiro, president and CEO, CTA. “With this kind of bipartisan momentum in the House, we are hopeful that the Senate will continue to push this legislation as expeditiously as possible.”
Over-the-counter hearing devices will be affordable, readily available and much more in line with what American consumers are willing to spend to improve their hearing. According to CTA's Personal Sound Amplification Products: a Study of Consumer Attitudes and Behavior, price is a significant barrier for consumers seeking help for a hearing deficiency. A pair of traditional hearing aids costs anywhere from $1,000 to $6,000, a price tag that many Americans simply cannot afford.
In contrast, over-the-counter devices are expected to be one-tenth that cost, ranging in price from $100 to $600.
“Passing this bill in the Senate and getting it signed into law will make an immediate impact in people's lives and bottom lines," Shapiro said. "Getting over-the-counter hearing aids on the same shelves as over-the-counter eyeglasses would be a major win for consumers with mild-to-moderate hearing loss. The high cost of hearing aids, the inconvenience and the cost of doctor appointments means nearly half of online U.S. adults – 98 million Americans – have some degree of hearing loss, but don't get the hearing assistance they need."
In support of the possible nonprescription status of hearing devices, CTA has developed a new logo and high-performance standard for wearable hearing devices.